Skip navigation

Empower

Hereditary cancer testing, made accessible

Empower is a genetic test for those who want to know more about their risk of developing cancer, why it might be common in their family, or want to inform treatment options following a cancer diagnosis.

Empower tests up to 53 genes associated with risk for common hereditary cancers using blood or saliva samples. Breast STAT panel results arrive in 5-7 days, with a full report in 2 weeks.

The Empower Hereditary Cancer Test is Designed with Your Practice in Mind

Four panel options with up to 53 genes across eight common hereditary cancer types, and a Breast STAT option to deliver results in time to build guided treatment plans.

BRCA1 & BRCA2

Genes: BRCA1, BRCA2

Breast, Ovarian, Endometrial cancers and Lynch Syndrome genes

Additional Genes: ATM, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53

Most commonly screened-for, actionable hereditary cancer genes across 8 cancer types*

Additional Genes: APC, AXIN2, BAP1, BARD1, BMPR1A, CDK4, CDKN2A, GALNT12, GREM1, HOXB13, MEN1, MITF, MSH3, MUTYH, NTHL1, POLD1, POLE, RNF43, RPS20, SMAD4, VHL

Includes multi-cancer panel plus additional genes with emerging evidence of elevated cancer risks

Additional Genes: CTNNA1, DICER1, KIT, MRE11, PDGFRA, RAD50, SDHA, SDHB, SDHC, SDHD, SMARCA4, TSC1, TSC2

*Breast STAT panel available with 11 breast cancer genes reported within 5-7 calendar days + 29 additional genes reported within 2 weeks. Breast STAT genes include ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NBN, PALB2, PTEN, STK11 and TP53.

Patient management recommendations based on medical guidelines

Actionable reports to guide next steps, including:

  • Detect cancer at its earliest, most treatable stage
  • Identify risk-reducing medications and surgeries
  • Inform surgical and therapeutic decisions following a cancer diagnosis
  • Notify family members to help them proactively manage hereditary cancer risk

Tyrer-Cuzick results for a comprehensive breast cancer risk assessment

  • Patients without a breast cancer-related gene mutation may still have increased risk for breast cancer based on their family cancer history and estrogen exposure over their lifetime.
  • Patients with ≥20% remaining lifetime breast cancer risk qualify for insurance coverage for preventive screenings including annual breast MRI surveillance in addition to an annual mammogram.
  • Tyrer-Cuzick evaluations are recommended by medical guidelines to calculate a woman’s breast cancer risk in the next 5 years and over the course of her lifetime.
  • Empower reports offer clear medical management information based on genetic and family history risk.
EMP-clin-Physian-portal

Natera is committed to patient affordability

Natera is proud to be an in-network provider with most health plans, including Aetna, Anthem, Cigna, and UnitedHealthcare.

 

For patients without adequate insurance coverage, Natera also offers self-pay pricing and compassionate care options.

EMP-clin-high-risk

Disclaimers : Bellcross CA, Peipins LA, McCarty FA, Rodriguez JL, et al. Genet Med. Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system. 2015 Jan;17(1):43–50. Patel SG, Ahnen DJ, Kinney AY, et al. Am J Gastroenterol. Knowledge and uptake of genetic counseling and colonoscopic screening among individuals at increased risk for lynch syndrome and their endoscopists from the family health promotion project. 2016 Feb;111(2):285-93.

Many patients at high risk for hereditary cancer are not tested

When to consider hereditary cancer testing

EMP_Clin_1-50 years or younger

Personal or family history of cancer at age 50 or younger

EMP_Clin_2-different cancer

Personal or family history of ovarian, male breast or pancreatic cancer

EMP_Clin_3-multiple

Multiple cancers or tumors on the same side of the family

EMP_Clin_4-Ashkenazi ancestry

Ashkenazi ancestry

EMP_Clin_5-Cancer patient

Your patient is concerned about other familial cancer patterns

Is Empower right for you?

We’re here to help you find out